Gestational trophoblastic neoplasia differential diagnosis

Revision as of 21:34, 28 February 2019 by Skazmi (talk | contribs)
Jump to navigation Jump to search

Gestational trophoblastic neoplasia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Gestational trophoblastic neoplasia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Gestational trophoblastic neoplasia differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Gestational trophoblastic neoplasia differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Gestational trophoblastic neoplasia differential diagnosis

CDC on Gestational trophoblastic neoplasia differential diagnosis

Gestational trophoblastic neoplasia differential diagnosis in the news

Blogs on Gestational trophoblastic neoplasia differential diagnosis

Directions to Hospitals Treating Gestational trophoblastic neoplasia

Risk calculators and risk factors for Gestational trophoblastic neoplasia differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Monalisa Dmello, M.B,B.S., M.D. [2]

Overview

Choriocarcinoma must be differentiated from non neoplastic diseases, neoplastic diseases, and other causes of bleeding during pregnancy.

Differentiating choriocarcinoma from other diseases

Choriocarcinoma must be differentiated from other non-neoplastic diseases such as:

Choriocarcinoma must be differentiated from other neoplastic diseases such as:

  • Invasive hydatidiform mole
  • Placental site trophoblastic tumor (PSTT)
  • Mixed germ cell tumor - esp. for testicular and ovarian tumors

Choriocarcinoma must be differentiated from other causes of bleeding during pregnancy:

Differential Diagnosis Clinical Features Karyotype Immunostaining Management
Presenting Complaints Potential for Neoplastic Conversion Beta Human Chorionic Gonadotropin (Beta-hCG) Baseline Levels History of Pregnancy Theca Leutin Cysts Metastatic Route Cytokeratin 18 HLA-G Human Chorionic Gonadotropin (hCG) Transformation-Related Protein 63 (P63) Human Placental Lactogen (hPL) Melanoma Cell Adhesion Molecule (Mel-CAM) Ki67
Complete Hydatidiform Mole
  • High rate of progression (15-20%)
  • Extremely high levels ( > 100000 mIU/ml in half of the patients
  • Not related
  • Present
  • Benign
  • 46, XX or 46 XY (Paternal dispermy)
  • Absent
  • Absent
  • Extremely elevated
  • Absent
  • Absent
  • Absent
  • Absent
  • Dilation and curettage (suction)
Partial Hydatidiform Mole
  • < 5 % progression rate
  • Highly elevated ( > 100000 mIU/ml in one in ten patients)
  • Not related
  • Absent
  • Benign
  • 69,XXY or XXY
  • Absent
  • Absent
  • Highly elevated
  • Absent
  • Absent
  • Absent
  • Absent
  • Dilation and curettage (suction)
Invasive Molar Pregnancy
  • High
  • Consequence of molar pregnancy
  • May be present
  • Hematogenous
  • 69,XXY or XXY
  • Positive
  • Positive
  • Highly elevated
  • Absent
  • Absent
  • Absent
  • Absent
Choriocarcinoma
  • Neoplastic
  • High
  • Present
  • Hematogenous
Placental-site Trophoblastic tumor (PSTT) and Epitheloid Trophoblastic Tumor (ETT)
Ovarian Tumors
Spontaneous Abortion
Ectopic Pregnancy
Normal Term Pregnancy
Clinical Features Complete Hydatidiform Mole Partial Hydatidiform Mole Invasive Molar Pregnancy Choriocarcinoma Placental-site trophoblastic tumor (PSTT) and Epithelioid trophoblastic tumor (ETT)
Presenting Complaints
Neoplastic Conversion
Beta Human Chorionic Gonadotropin (Beta-hCG) baseline levels
  • High
  • High
  • Moderatley elevated (< 1000 mIU/ml in majority of patients)
History of Pregnancies
Metastatic Route
Management

References